Heron Therapeutics Q1 net product sales up 26% to $29.6M; net loss narrows to $32.8M

HERON THERAPEUTICS, INC. /DE/

2023-Q1 EPS reported -$0.27 revenue$29,615,000

Net product sales $29.6M vs $23.5M in Q1 2022, driven by oncology franchise growth of 15%.
Net loss $32.8M ($0.27/share), improved from $63.9M ($0.63/share) a year ago.
Cash and investments $60.0M at March 31, 2023, down from $84.9M at Dec. 31, 2022.
Appointed Craig Collard as CEO in April; APONVIE launched in March with $0.3M initial sales.
ZYNRELEF sNDA PDUFA date set for Oct. 23, 2023; 907 unique accounts have purchased since launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.